



PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 5/19/16
LAST REVIEW DATE: 9/20/18
LAST CRITERIA REVISION DATE: 9/20/18
ARCHIVE DATE:

VENCLEXTA™ (venetoclax) oral tablet

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the request form in its entirety with the chart notes as documentation. All requested data must be provided. Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 5/19/16
LAST REVIEW DATE: 9/20/18
LAST CRITERIA REVISION DATE: 9/20/18
ARCHIVE DATE:

VENCLEXTA™ (venetoclax) oral tablet (cont.)

Criteria:

- **Criteria for initial therapy:** Venclexta (venetoclax) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is an Oncologist
 2. Individual is 18 years of age or older
 3. A confirmed diagnosis of **ONE** of the following:
 - Chronic lymphocytic leukemia (CLL), with or without 17p deletion, in an individual who has received at least one prior therapy
 - Small lymphocytic lymphoma (SLL), with or without 17p deletion, in an individual who has received at least one prior therapy
 - Other request for a specific oncologic direct treatment use that is found and listed in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1 and 2A
 4. Individual has a concurrent prescription for allopurinol and hydration for prophylaxis of tumor lysis syndrome (TLS) before the first dose is administered
 5. **ALL** of the following baseline tests have been completed before initiation of treatment:
 - Pre-existing abnormalities in serum potassium, uric acid, phosphorus, and calcium have been corrected
 - Comprehensive metabolic panel
 - Complete blood count with differential
 - Pregnancy test in a woman of child bearing age
 6. There are **NO** contraindications:
 - Contraindications include:
 - Simultaneous use with strong inhibitors of CYP3A, at initiation and during the ramp-up phase, such as ketoconazole, conivaptan, clarithromycin, indinavir, itraconazole, lopinavir, ritonavir, telaprevir, posaconazole and voriconazole
 7. Will not be used with strong or moderate CYP3A4 inducers such as carbamazepine, phenytoin, rifampin, St. John's wort, bosentan, efavirenz, etravirine, modafinil, or nafcillin
 8. Individual is not to receive live attenuated vaccine(s) prior to, during, or after treatment, unless B-cells have recovered
 9. Will not be used in an individual with severe hepatic impairment (total bilirubin > 3x ULN)

Initial approval duration:

42 tabs Starting Pack for 1 month
120 tabs (100 mg) per 30 days for 5 months

VENCLEXTA™ (venetoclax) oral tablet (cont.)

- **Criteria for continuation of continuation of coverage (renewal request):** Venclexta (venetoclax) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Individual continues to be seen by an Oncologist
 2. Individual's cancer responded or has not worsened while on therapy
 3. Individual has been adherent with the medication
 4. Individual has not developed any contraindications or other significant level 4 adverse drug effects that may exclude continued use
 - Contraindications as listed in the criteria for initial therapy section
 - Significant adverse effect such as:
 - Tumor Lysis Syndrome
 - Neutropenia
 5. There are no significant interacting drugs

Renewal duration: 120 tabs (100 mg) per 30 days for 12 months

Description:

Venclexta (venetoclax) is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

CLL/SLL are different expressions of the same disease and are managed in the same way. CLL/SLL is characterized by progressive accumulation of small, mature lymphocytic leukemic cells in the peripheral blood, bone marrow, and lymphoid tissue. In CLL the abnormal lymphocytes are predominantly found in the blood, while in SLL the bulk is found in the lymph nodes, bone marrow, and other lymphoid tissues

Several recurring lesions have been identified to have prognostic relevance. Deletions in chromosomes 13q, 17p, and 11q; and trisomy 12 are recognized as negative prognostic factors of the disease affecting prognosis and drug resistance. The 17p deletion is associated with poor outcomes that include a short treatment-free interval, short survival (median survival of 32 months), and poor response to chemotherapy. This deletion is more common in patients who have received prior therapy. Choice of therapy is made based on prognosis, age, comorbid conditions, and cytogenetic abnormalities.

CLL is a lymphoproliferative disorder that accounts for 30% of adult leukemia and 25% of non-Hodgkin lymphoma (NHL); it is a heterogeneous disease with an extremely variable course. It is the most prevalent adult leukemia in Western countries with a median age of diagnosis of 71 years of age.

CLL is characterized by high-level expression of B-cell lymphoma-2 (BCL-2) protein in all patients. It has been well documented that BCL-2 plays a role in cellular apoptosis and is a target for drug therapy. The BCL-2

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 5/19/16
LAST REVIEW DATE: 9/20/18
LAST CRITERIA REVISION DATE: 9/20/18
ARCHIVE DATE:

VENCLEXTA™ (venetoclax) oral tablet (cont.)

protein is a major apoptotic regulator. The ability to nullify the death signal in cancer cells is a key hallmark of cancer. BCL-2 plays a major role in tumor genesis and chemotherapy resistance.

Because there is no cure for CLL, choice of therapy is made based on prognosis, age, and comorbid conditions.

Venclexta (venetoclax) is a selective inhibitor of BCL-2 protein, an anti-apoptotic protein. It helps restore the process of apoptosis by binding directly to the BCL-2 protein inhibiting the effects of BCL-2. Venclexta (venetoclax) promotes apoptosis or cell death by restoring normal cell death pathways within cancerous B-cells. Venclexta (venetoclax) is the second targeted oral agent for CLL with the 17p deletion. Imbruvica (ibrutinib) was approved for CLL with the 17p deletion in July 2014.

Definitions:

Suggested Treatment Regimens – per NCCN Guidelines (version 1.2019)

CLL/SLL w/del(17p)/TP53 mutation:

First-line Therapy for CLL/SLL w/del(17p)/TP53 mutation	Relapsed/Refractory CLL/SLL w/del(17p)/TP53 mutation
Preferred:	Preferred:
Imbruvica (ibrutinib)	Imbruvica (ibrutinib) – category 1
Other recommended:	Venclexta (venetoclax) + rituximab – category 1
Campath (alemtuzumab) ± rituximab	Zydelig (idelalisib) + rituximab
High-dose methylprednisolone (HDMP) + rituximab	Venclexta (venetoclax)
Gazyva (obinutuzumab)	Other recommended:
Post 1st line maintenance:	Calquence (acalabrutinib)
Revlimid (lenalidomide) for high-risk patients – category 3	Campath (alemtuzumab) ± rituximab
	HDMP + rituximab
	Zydelig (idelalisib)
	Revlimid (lenalidomide) ± rituximab
	Arzerra (ofatumumab)
Post 2nd line maintenance:	
(for CR or PR after relapsed or refractory therapy)	
Revlimid (lenalidomide)	
Arzerra (ofatumumab) – category 2B	

CLL/SLL wo/del(17p) /TP53 mutation:

Relapsed/Refractory CLL/SLL wo/del(17p) /TP53 mutation	Relapsed/Refractory CLL/SLL wo/del(17p) /TP53 mutation
Frail with significant co-morbidities or age ≥ 65	Age < 65 without significant co-morbidities
Younger patients without significant co-morbidities	
Preferred:	Preferred:
Imbruvica (ibrutinib) – category 1	Imbruvica (ibrutinib) – category 1
Venclexta (venetoclax) + rituximab – category 1	Venclexta (venetoclax) + rituximab – category 1
Zydelig (idelalisib) + rituximab	Zydelig (idelalisib) + rituximab

**PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS**

**ORIGINAL EFFECTIVE DATE: 5/19/16
LAST REVIEW DATE: 9/20/18
LAST CRITERIA REVISION DATE: 9/20/18
ARCHIVE DATE:**

VENCLEXTA™ (venetoclax) oral tablet (cont.)

Other recommended:	Other recommended:
Calquence (acalabrutinib)	Calquence (acalabrutinib)
Campath (alemtuzumab) ± rituximab	Campath (alemtuzumab) ± rituximab
Chlorambucil + rituximab	Bendeka (bendamustine) + rituximab
Reduced dose fludarabine, cyclophosphamide, rituximab (FCR)	Fludarabine + cyclophosphamide (FC)
HDMP + rituximab	FCR
Zydelig (idelalisib)	HDMP + rituximab
Revlimid (lenalidomide) ± rituximab	Zydelig (idelalisib)
Gazyva (obinutuzumab)	Revlimid (lenalidomide) ± rituximab
Arzerra (ofatumumab)	Gazyva (obinutuzumab)
Reduced dose pentostatin, cyclophosphamide, rituximab (PCR)	Arzerra (ofatumumab)
Venclexta (venetoclax)	PCR
Dose dense rituximab – category 2B	Venclexta (venetoclax)
Bendeka (bendamustine) + rituximab (BR) – category 2B	BR + Imbruvica (ibrutinib) – category 2B
BR + Imbruvica (ibrutinib) – category 2B	BR + Zydelig (idelalisib) – category 2B
BR+ Zydelig (idelalisib) – category 3	
Post 2nd line maintenance: (for CR or PR after relapsed or refractory therapy)	
Revlimid (lenalidomide)	
Arzerra (ofatumumab) – category 2B	

Resources:

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.

Venclexta. Package Insert. Revised by manufacturer 4/2016. Accessed 03-21-2017.

Venclexta. Package Insert. Revised by manufacturer 4/2016. Accessed 05-17-2016.

Venclexta. Package Insert. Revised by manufacturer 12/2017. Accessed 04-18-2018.

Venclexta. Package Insert. Revised by manufacturer 06/2018. Accessed 09-09-2018.

NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 5.2018, Mar 26, 2018. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf

NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 1.2019, Aug 9, 2018. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf



An Independent Licensee of the Blue Cross and Blue Shield Association

Fax completed prior authorization request form to 602-864-3126 or email to pharmacyprecert@azblue.com. Call 866-325-1794 to check the status of a request. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at www.azblue.com/pharmacy.

Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.

REQUIRED: Office notes, labs, and medical testing relevant to the request that show medical justification are required.

Member Information			
Member Name (first & last):	Date of Birth:	Gender:	BCBSAZ ID#:
Address:	City:	State:	Zip Code:

Prescribing Provider Information			
Provider Name (first & last):	Specialty:	NPI#:	DEA#:
Office Address:	City:	State:	Zip Code:
Office Contact:	Office Phone:	Office Fax:	

Dispensing Pharmacy Information		
Pharmacy Name:	Pharmacy Phone:	Pharmacy Fax:

Requested Medication Information			
Medication Name:	Strength:	Dosage Form:	
Directions for Use:	Quantity:	Refills:	Duration of Therapy/Use:

Check if requesting **brand** only Check if requesting **generic**

Check if requesting continuation of therapy (prior authorization approved by BCBSAZ expired)

Turn-Around Time For Review	
<input type="checkbox"/> Standard <input type="checkbox"/> Urgent. Sign here: _____	<input type="checkbox"/> Exigent (requires prescriber to include a written statement)

Clinical Information

1. **What is the diagnosis? Please specify below.**
 ICD-10 Code: _____ Diagnosis Description: _____

2. Yes No **Was this medication started on a recent hospital discharge or emergency room visit?**

3. Yes No **There is absence of ALL contraindications.**

4. **What medication(s) has the individual tried and failed for this diagnosis? Please specify below.**
 Important note: Samples provided by the provider are not accepted as continuation of therapy or as an adequate trial and failure.

Medication Name, Strength, Frequency	Dates started and stopped or Approximate Duration	Describe response, reason for failure, or allergy

5. **Are there any supporting labs or test results? Please specify below.**

Date	Test	Value

Pharmacy Prior Authorization Request Form

6. Is there any additional information the prescribing provider feels is important to this review? Please specify below.
For example, explain the negative impact on medical condition, safety issue, reason formulary agent is not suitable to a specific medical condition, expected adverse clinical outcome from use of formulary agent, or reason different dosage form or dose is needed.

Signature affirms that information given on this form is true and accurate and reflects office notes

Prescribing Provider's Signature:	Date:
-----------------------------------	-------

Please note: Some medications may require completion of a drug-specific request form.

Incomplete forms or forms without the chart notes will be returned.

Office notes, labs, and medical testing relevant to the request that show medical justification are required.